Foundation Showcased in BusinessWeek

April 3, 2008

An article today in BusinessWeek online showcases the Foundation’s unique business model and its promising investments in pharmaceutical companies to develop drugs for cystic fibrosis. The story highlights the positive early results of an ongoing clinical trial of VX-770, an oral drug that targets the basic defect in CF being developed by Vertex Pharmaceuticals.

Read the full story from BusinessWeek online.

Learn more about VX-770.